title: Topical nepafenac 0.1% alone versus prednisolone acetate 1% as postoperative anti-inflammatory agents in small gauge vitrectomy.
abstract: OBJECTIVE
  To compare the efficacy of postoperative topical nepafenac (0.1%) with prednisolone acetate (1%) as anti-inflammatory agents in eyes undergoing Transscleral Sutureless Vitrectomy (TSV).
  
  
  METHODS
  Prospective, double-blind, randomized, single center clinical study.
  
  
  METHODS
  Eighty eyes of 76 subjects, who underwent small gauge vitrectomy, were included in the study. The subjects who fulfilled the inclusion criteria were randomized to either topical nepafenac only (Group 1) or prednisolone acetate only (Group 2), to be used as postoperative anti-inflammatory agents. The subjects were reviewed on days 1, 30, and 90. Ocular and adnexal inflammation was appropriately graded using the standardized classification. Grading of ocular pain was done on the Visual Analog Scale (VAS).
  
  
  METHODS
  The Wilcoxon rank-sum test, using two-sided analysis, was used.
  
  
  RESULTS
  During the follow-up, both Group 1 and Group 2 did not have a significant difference related to the grade of the anterior chamber inflammation (P > 0.05) or adnexal inflammation (P > 0.05). Pain perception was less in the subjects in Group 1 as compared to subjects in Group 2, but was not statistically significant (P > 0.05).
  
  
  CONCLUSIONS
  Postoperative topical nepafenac was non-inferior to prednisolone acetate in reducing postoperative ocular inflammation in eyes undergoing TSV.
authors.affiliation: Department of Retina and Vitreous, Retina Foundation, Rajbhavan Road, Ahmedabad, Gujarat, India.
authors.forename: Manish
authors.initials: M
authors.lastname: Nagpal
authors.forename: Sarang
authors.initials: S
authors.lastname: Lambat
authors.forename: Navneet
authors.initials: N
authors.lastname: Mehrotra
authors.forename: Gaurav
authors.initials: G
authors.lastname: Paranjpe
authors.forename: Harsh
authors.initials: H
authors.lastname: Yadav
authors.forename: Sidharth
authors.initials: S
authors.lastname: Bhardwaj
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D044482:Benzeneacetamides / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D009877:Endophthalmitis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D010648:Phenylacetates / Q000008:administration & dosage*; D011183:Postoperative Complications / Q000188:drug therapy* / Q000209:etiology; D011239:Prednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011355:Prodrugs; D011446:Prospective Studies; D012590:Sclera / Q000601:surgery; D016896:Treatment Outcome; D014792:Visual Acuity; D014821:Vitrectomy / Q000009:adverse effects* / Q000379:methods
chemical_list: D000893:Anti-Inflammatory Agents; D044482:Benzeneacetamides; D009883:Ophthalmic Solutions; D010648:Phenylacetates; D011355:Prodrugs; C414203:nepafenac; C009935:prednisolone acetate; D011239:Prednisolone